159 related articles for article (PubMed ID: 26358014)
1. PIK3CA mutation analysis in Chinese patients with surgically resected cervical cancer.
Xiang L; Jiang W; Li J; Shen X; Yang W; Yang G; Wu X; Yang H
Sci Rep; 2015 Sep; 5():14035. PubMed ID: 26358014
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
Chung TKH; Cheung TH; Yim SF; Yu MY; Chiu RWK; Lo KWK; Lee IPC; Wong RRY; Lau KKM; Wang VW; Worley MJ; Elias KM; Fiascone SJ; Smith DI; Berkowitz RS; Wong YF
Gynecol Oncol; 2017 Aug; 146(2):334-339. PubMed ID: 28587748
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
[TBL] [Abstract][Full Text] [Related]
4. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and its association with clinicopathological findings in Indian patients.
Ahmad F; Badwe A; Verma G; Bhatia S; Das BR
Med Oncol; 2016 Jul; 33(7):74. PubMed ID: 27282497
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers.
Xiang L; Li J; Jiang W; Shen X; Yang W; Wu X; Yang H
Oncotarget; 2015 Mar; 6(7):4968-75. PubMed ID: 25669975
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.
Bando H; Yoshino T; Shinozaki E; Nishina T; Yamazaki K; Yamaguchi K; Yuki S; Kajiura S; Fujii S; Yamanaka T; Tsuchihara K; Ohtsu A
BMC Cancer; 2013 Sep; 13():405. PubMed ID: 24006859
[TBL] [Abstract][Full Text] [Related]
7. Frequency, characterization, and prognostic analysis of PIK3CA gene mutations in Chinese esophageal squamous cell carcinoma.
Hou J; Jiang D; Zhang J; Gavine PR; Xu S; Liu Y; Xu C; Huang J; Tan Y; Wang H; Lu Y; Zheng L; Hou Y; Tan L
Hum Pathol; 2014 Feb; 45(2):352-8. PubMed ID: 24360885
[TBL] [Abstract][Full Text] [Related]
8. Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma.
Song Z; Yu X; Zhang Y
Cancer Med; 2016 Oct; 5(10):2694-2700. PubMed ID: 27554588
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3'-kinase pathway alterations might be associated with favorable prognosis.
Dong Y; Yang X; Wong O; Zhang X; Liang Y; Zhang Y; Wong W; Nong L; Liao Q; Li T
Hum Pathol; 2012 Aug; 43(8):1197-205. PubMed ID: 22209294
[TBL] [Abstract][Full Text] [Related]
11. Elucidating the prognostic significance of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese patients with metastatic colorectal cancer.
Ma BB; Mo F; Tong JH; Wong A; Wong SC; Ho WM; Wu C; Lam PW; Chan KF; Chan TS; Tsui WM; Tsang AK; Fung MN; Chan AT; To KF
Asia Pac J Clin Oncol; 2015 Jun; 11(2):160-9. PubMed ID: 25865669
[TBL] [Abstract][Full Text] [Related]
12.
Liu SY; Chen W; Chughtai EA; Qiao Z; Jiang JT; Li SM; Zhang W; Zhang J
World J Gastroenterol; 2017 Apr; 23(14):2585-2591. PubMed ID: 28465643
[TBL] [Abstract][Full Text] [Related]
13. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.
Martell K; McIntyre JB; Kornaga EN; Chan AMY; Phan T; Köbel M; Enwere EK; Dean ML; Ghatage P; Lees-Miller SP; Doll CM
Gynecol Oncol; 2020 Sep; 158(3):776-784. PubMed ID: 32653099
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery.
Martell K; McIntyre JB; Abedin T; Kornaga EN; Chan AMY; Enwere E; Köbel M; Dean ML; Phan T; Ghatage P; Lees-Miller SP; Doll CM
Int J Gynecol Pathol; 2024 Mar; 43(2):158-170. PubMed ID: 37668363
[TBL] [Abstract][Full Text] [Related]
16. PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F; Wheler JJ; Naing A; Stepanek VM; Falchook GS; Fu S; Garrido-Laguna I; Tsimberidou AM; Piha-Paul SA; Moulder SL; Lee JJ; Luthra R; Hong DS; Kurzrock R
Oncotarget; 2012 Dec; 3(12):1566-75. PubMed ID: 23248156
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.
McIntyre JB; Wu JS; Craighead PS; Phan T; Köbel M; Lees-Miller SP; Ghatage P; Magliocco AM; Doll CM
Gynecol Oncol; 2013 Mar; 128(3):409-14. PubMed ID: 23266353
[TBL] [Abstract][Full Text] [Related]
18. PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.
Wang L; Shan L; Zhang S; Ying J; Xue L; Yuan Y; Xie Y; Lu N
PLoS One; 2014; 9(7):e103021. PubMed ID: 25054828
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA mutation is associated with a favorable prognosis among patients with curatively resected esophageal squamous cell carcinoma.
Shigaki H; Baba Y; Watanabe M; Murata A; Ishimoto T; Iwatsuki M; Iwagami S; Nosho K; Baba H
Clin Cancer Res; 2013 May; 19(9):2451-9. PubMed ID: 23532889
[TBL] [Abstract][Full Text] [Related]
20. Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.
Shen Y; Wang J; Han X; Yang H; Wang S; Lin D; Shi Y
PLoS One; 2013; 8(12):e81628. PubMed ID: 24339949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
